CCL2 and diabetic kidney disease: They have also reduced the production of chemokines, such as MCP-1, TGF-β1, and FN, activate NF-κB, and inhibited sugar-induced degradation of IκBα, confirming the efficacy of sesquiterpene lactones as drug candidates for the treatment of diabetic nephropathy [158, 162].